Creating new treatments to prevent and treat urinary tract infections.
Development of anti-adhesin mAbs and high-affinity ligand mimetics to treat and prevent UTIs
This study is looking for new ways to help people with urinary tract infections (UTIs), especially those caused by bacteria that don't respond to regular antibiotics, by creating special treatments that stop these germs from sticking to the urinary tract, which could lead to better options for anyone dealing with frequent UTIs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11042755 on NIH RePORTER |
What this research studies
This research focuses on developing new therapies to combat urinary tract infections (UTIs), particularly those caused by antibiotic-resistant bacteria. The approach involves creating monoclonal antibodies and small molecules that can block the adhesion of harmful bacteria, preventing them from causing infections. By targeting the mechanisms that allow these bacteria to attach and thrive in the urinary tract, the research aims to provide effective alternatives to traditional antibiotics. Patients may benefit from these innovative treatments that could reduce the reliance on antibiotics and improve outcomes for those suffering from recurrent UTIs.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who experience recurrent urinary tract infections or are at high risk for catheter-associated UTIs.
Not a fit: Patients with UTIs caused by non-bacterial pathogens or those who do not have recurrent infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for urinary tract infections that do not rely on antibiotics, thereby reducing antibiotic resistance.
How similar studies have performed: Other research has shown promise in developing antibody-based therapies for bacterial infections, indicating that this approach could be effective.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Hultgren, Scott J. — Washington University
- Study coordinator: Hultgren, Scott J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.